Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response
The DOI matches its Crossref record.
Abstract
Twenty-nine boys with attention deficit disorder/hyperactivity were randomly assigned to receive desipramine (DMI; n = 17) or placebo (n = 12) for 14 days in a noncrossover, double-blind study. There was immediate behavioral improvement with DMI at day 3 that was sustained for 2 weeks; behavioral improvement did not correlate with plasma concentrations of DMI, hydroxy-DMI, or their sum at either days 3 or 14. There were no untoward side effects; there was a drug-induced increase in pulse and diastolic blood pressure. During drug therapy, the urinary excretion of norepinephrine, vanillymandelic acid, and 3-methoxy-4-hydroxyphenylglycol (MHPG) was decreased at both days 3 and 14. The plasma MHPG level was decreased at days 3 and 14 and (standing) plasma NE levels increased at day 14. The decreases in both urinary and plasma MHPG levels showed significant correlations with behavioral improvement during the second week. These data corroborate previous findings on sympathomimetic effects of tricyclic antidepressants in children and support a noradrenergic mechanism in the mediation of drug effects on attention deficit disorder/hyperactivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Dulcan, M. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199710001-00007 · Cited by 628
Neurobiology of Attention Deficit Disorder With Hyperactivity: Where Have We Come in 50 Years?
ZAMETKIN, A. J., & RAPOPORT, J. L. (1987) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198709000-00011 · Cited by 348
Self-citationTreatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence
Brown, R. T., Amler, R. W., Freeman, W. S., Perrin, J. M., Stein, M. T., Feldman, H. M., Pierce, K., Wolraich, M. L., & and the Committee on Quality Improvement, S. O. A.-D. D. (2005) · Pediatrics · doi:10.1542/peds.2004-2560 · Cited by 330
A Double-Blind Placebo Controlled Study of Desipramine in the Treatment of ADD: I. Efficacy
BIEDERMAN, J., BALDESSARINI, R. J., WRIGHT, V., KNEE, D., & HARMATZ, J. S. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198909000-00022 · Cited by 310
Metadata
- Authors
- Donnelly, M., Zametkin, A. J., Rapoport, J. L., Ismond, D. R., Weingartner, H., Lane, E., Oliver, J., Linnoila, M., & Potter, W. Z.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1986-01
- Volume
- 39
- Issue
- 1
- Pages
- 72-81
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2120155005
- Cited by
- 100
- References
- 0
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. https://app.cochat.ai/papers/10.1038/clpt.1986.13
- The paper
- Donnelly, M., Zametkin, A. J., Rapoport, J. L., Ismond, D. R., Weingartner, H., Lane, E., Oliver, J., Linnoila, M., & Potter, W. Z. (1986). Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.1986.13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.